DDI_ID$Drug_1_Name$Drug_1_Drugbankid$Drug_1_type$Drug_2_Name$Drug_2_Drugbankid$Is_DDI$DDI_Type$Drug_2_type$Sentence_Text
DDI-DrugBank.d0.s2.p0$Naltrexone$DB00704$drug$Acamprosate$DB00659$true$mechanism$drug$Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
DDI-DrugBank.d104.s0.p1$Fenfluramine$DB00574$drug$Guanethidine$DB01170$true$effect$drug$Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d104.s0.p2$Fenfluramine$DB00574$drug$Methyldopa$DB00968$true$effect$drug$Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d104.s0.p3$Fenfluramine$DB00574$drug$Reserpine$DB00206$true$effect$drug$Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d106.s6.p0$Propranolol$DB00571$drug$Nisoldipine$DB00401$true$effect$drug$Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
DDI-DrugBank.d106.s8.p0$Quinidine$DB00908$drug$Nisoldipine$DB00401$true$mechanism$drug$Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
DDI-DrugBank.d106.s9.p0$Nisoldipine$DB00401$drug$Quinidine$DB00908$true$mechanism$drug$The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
DDI-DrugBank.d107.s17.p2$Enalapril$DB00584$drug$Lithium$DB01356$true$advise$drug$It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
DDI-DrugBank.d108.s0.p1$Isocarboxazid$DB01247$drug$Disulfiram$DB00822$true$advise$drug$Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
DDI-DrugBank.d11.s4.p1$Paroxetine$DB00715$drug$Atomoxetine$DB00289$true$mechanism$drug$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DDI-DrugBank.d11.s4.p3$Fluoxetine$DB00472$drug$Atomoxetine$DB00289$true$mechanism$drug$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DDI-DrugBank.d112.s0.p0$Probenecid$DB01032$drug$Penciclovir$DB00299$true$mechanism$drug$Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
DDI-DrugBank.d120.s2.p4$Diphenidol$DB01231$drug$Apomorphine$DB00714$true$effect$drug$apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
DDI-DrugBank.d121.s1.p0$Probenecid$DB01032$drug$Cefprozil$DB01150$true$mechanism$drug$Concomitant administration of probenecid doubled the AUC for cefprozil.
DDI-DrugBank.d122.s3.p1$Chloramphenicol$DB00446$drug$Ceftazidime$DB00438$true$effect$drug$Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
DDI-DrugBank.d123.s0.p2$Ciprofloxacin$DB00537$drug$Caffeine$DB00201$true$mechanism$drug$Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d123.s14.p2$Phenytoin$DB00252$drug$Ciprofloxacin$DB00537$true$mechanism$drug$Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
DDI-DrugBank.d123.s15.p3$Probenecid$DB01032$drug$Ciprofloxacin$DB00537$true$mechanism$drug$Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DDI-DrugBank.d123.s15.p4$Probenecid$DB01032$drug$Ciprofloxacin$DB00537$true$mechanism$drug$Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DDI-DrugBank.d123.s16.p7$Ciprofloxacin$DB00537$drug$Theophylline$DB00277$true$mechanism$drug$Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
DDI-DrugBank.d123.s2.p2$Ciprofloxacin$DB00537$drug$Cyclosporine$DB00091$true$effect$drug$Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
DDI-DrugBank.d123.s3.p4$Ciprofloxacin$DB00537$drug$Glyburide$DB01016$true$effect$drug$Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d123.s5.p3$Methotrexate$DB00563$drug$Ciprofloxacin$DB00537$true$mechanism$drug$Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
DDI-DrugBank.d123.s7.p0$Methotrexate$DB00563$drug$Ciprofloxacin$DB00537$true$advise$drug$Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
DDI-DrugBank.d123.s8.p10$Ciprofloxacin$DB00537$drug$Magnesium$DB01378$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p13$Ciprofloxacin$DB00537$drug$Sucralfate$DB00364$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p15$Ciprofloxacin$DB00537$drug$Calcium$DB01373$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p16$Ciprofloxacin$DB00537$drug$Iron$DB01592$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p17$Ciprofloxacin$DB00537$drug$Zinc$DB01593$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p18$Ciprofloxacin$DB00537$drug$Ciprofloxacin$DB00537$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p107$Cyclosporine$DB00091$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p120$Pimozide$DB01100$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p125$Carbamazepine$DB00564$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p129$Fentanyl$DB00813$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p134$Alprazolam$DB00404$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p135$Triazolam$DB00897$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p30$Dapsone$DB00250$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p44$Disopyramide$DB00280$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p57$Quinine$DB00468$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p69$Amiodarone$DB01118$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p80$Quinidine$DB00908$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p90$Warfarin$DB00682$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p99$Tacrolimus$DB00864$drug$Saquinavir$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s30.p3$Phenobarbital$DB01174$drug$Saquinavir$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d124.s30.p6$Phenytoin$DB00252$drug$Saquinavir$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d124.s30.p8$Dexamethasone$DB01234$drug$Saquinavir$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d124.s30.p9$Carbamazepine$DB00564$drug$Saquinavir$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d130.s2.p0$Lincomycin$DB01627$drug$Erythromycin$DB00199$true$effect$drug$Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
DDI-DrugBank.d131.s0.p8$Alprazolam$DB00404$drug$Ethanol$DB00898$true$effect$drug$The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s1.p1$Imipramine$DB00458$drug$Alprazolam$DB00404$true$mechanism$drug$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DDI-DrugBank.d131.s1.p2$Desipramine$DB01151$drug$Alprazolam$DB00404$true$mechanism$drug$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DDI-DrugBank.d131.s10.p10$Alprazolam$DB00404$drug$Nifedipine$DB01115$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p6$Alprazolam$DB00404$drug$Ergotamine$DB00696$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p7$Alprazolam$DB00404$drug$Cyclosporine$DB00091$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p8$Alprazolam$DB00404$drug$Amiodarone$DB01118$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p9$Alprazolam$DB00404$drug$Nicardipine$DB00622$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s5.p7$Fluoxetine$DB00472$drug$Alprazolam$DB00404$true$mechanism$drug$Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
DDI-DrugBank.d131.s8.p63$Alprazolam$DB00404$drug$Diltiazem$DB00343$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8.p64$Alprazolam$DB00404$drug$Isoniazid$DB00951$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8.p66$Alprazolam$DB00404$drug$Erythromycin$DB00199$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8.p67$Alprazolam$DB00404$drug$Clarithromycin$DB01211$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s9.p3$Alprazolam$DB00404$drug$Sertraline$DB01104$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
DDI-DrugBank.d131.s9.p4$Alprazolam$DB00404$drug$Paroxetine$DB00715$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
DDI-DrugBank.d132.s0.p4$Diflunisal$DB00861$drug$Warfarin$DB00682$true$effect$drug$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s0.p5$Diflunisal$DB00861$drug$Acenocoumarol$DB01418$true$effect$drug$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s0.p6$Diflunisal$DB00861$drug$Phenprocoumon$DB00946$true$effect$drug$Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s11.p3$Diflunisal$DB00861$drug$Acetaminophen$DB00316$true$mechanism$drug$Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
DDI-DrugBank.d132.s13.p2$Diflunisal$DB00861$drug$Acetaminophen$DB00316$true$advise$drug$Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
DDI-DrugBank.d132.s14.p0$Diflunisal$DB00861$drug$Acetaminophen$DB00316$true$effect$drug$Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
DDI-DrugBank.d132.s16.p2$Diflunisal$DB00861$drug$Methotrexate$DB00563$true$advise$drug$Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
DDI-DrugBank.d132.s20.p3$Diflunisal$DB00861$drug$Indomethacin$DB00328$true$mechanism$drug$Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DDI-DrugBank.d132.s21.p0$Indomethacin$DB00328$drug$Diflunisal$DB00861$true$effect$drug$In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DDI-DrugBank.d132.s22.p0$Indomethacin$DB00328$drug$Diflunisal$DB00861$true$advise$drug$Therefore, indomethacin and diflunisal should not be used concomitantly.
DDI-DrugBank.d132.s26.p2$Diflunisal$DB00861$drug$Sulindac$DB00605$true$mechanism$drug$Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
DDI-DrugBank.d132.s27.p4$Diflunisal$DB00861$drug$Naproxen$DB00788$true$mechanism$drug$Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
DDI-DrugBank.d132.s5.p3$Diflunisal$DB00861$drug$Hydrochlorothiazide$DB00999$true$mechanism$drug$Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
DDI-DrugBank.d132.s6.p0$Diflunisal$DB00861$drug$Hydrochlorothiazide$DB00999$true$effect$drug$Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
DDI-DrugBank.d132.s8.p0$Diflunisal$DB00861$drug$Furosemide$DB00695$true$effect$drug$Diflunisal decreased the hyperuricemic effect of furosemide.
DDI-DrugBank.d135.s7.p2$Ketoconazole$DB01026$drug$Lapatinib$DB01259$true$mechanism$drug$Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
DDI-DrugBank.d135.s8.p2$Carbamazepine$DB00564$drug$Lapatinib$DB01259$true$mechanism$drug$Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
DDI-DrugBank.d140.s10.p5$Atorvastatin$DB01076$drug$Norethindrone$DB00717$true$mechanism$drug$Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s10.p6$Atorvastatin$DB01076$drug$Ethinyl Estradiol$DB00977$true$mechanism$drug$Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s4.p5$Colestipol$DB00375$drug$Atorvastatin$DB01076$true$mechanism$drug$Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
DDI-DrugBank.d140.s5.p0$Atorvastatin$DB01076$drug$Colestipol$DB00375$true$effect$drug$However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
DDI-DrugBank.d140.s7.p3$Atorvastatin$DB01076$drug$Digoxin$DB00390$true$mechanism$drug$Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
DDI-DrugBank.d140.s9.p5$Atorvastatin$DB01076$drug$Erythromycin$DB00199$true$mechanism$drug$Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d141.s12.p2$Cerivastatin$DB00439$drug$Erythromycin$DB00199$true$mechanism$drug$ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d143.s10.p0$Amiodarone$DB01118$drug$Indinavir$DB00224$true$mechanism$drug$A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
DDI-DrugBank.d144.s0.p0$Ketoconazole$DB01026$drug$Budesonide$DB01222$true$mechanism$drug$Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
DDI-DrugBank.d144.s1.p14$Ritonavir$DB00503$drug$Budesonide$DB01222$true$advise$drug$If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1.p17$Indinavir$DB00224$drug$Budesonide$DB01222$true$advise$drug$If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1.p19$Saquinavir$DB01232$drug$Budesonide$DB01222$true$advise$drug$If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1.p20$Erythromycin$DB00199$drug$Budesonide$DB01222$true$advise$drug$If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1.p5$Ketoconazole$DB01026$drug$Budesonide$DB01222$true$advise$drug$If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d148.s4.p0$Argatroban$DB00278$drug$Warfarin$DB00682$true$effect$drug$However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
DDI-DrugBank.d151.s0.p0$Folic Acid$DB00158$drug$Phenobarbital$DB01174$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d151.s0.p1$Folic Acid$DB00158$drug$Phenytoin$DB00252$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d151.s0.p2$Folic Acid$DB00158$drug$Primidone$DB00794$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d151.s2.p0$Leucovorin$DB00650$drug$Methotrexate$DB00563$true$effect$drug$However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
DDI-DrugBank.d154.s3.p0$Phenobarbital$DB01174$drug$Fenoprofen$DB00573$true$mechanism$drug$Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
DDI-DrugBank.d158.s6.p5$Furazolidone$DB00614$drug$Amphetamine$DB00182$true$mechanism$drug$MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d160.s0.p0$Ethambutol$DB00330$drug$Aluminum hydroxide$DB06723$true$mechanism$drug$The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
DDI-DrugBank.d160.s1.p0$Ethambutol$DB00330$drug$Aluminum hydroxide$DB06723$true$advise$drug$It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
DDI-DrugBank.d162.s11.p0$Lithium$DB01356$drug$Hydrochlorothiazide$DB00999$true$advise$drug$Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
DDI-DrugBank.d162.s5.p2$Cholestyramine$DB01432$drug$Hydrochlorothiazide$DB00999$true$mechanism$drug$Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
DDI-DrugBank.d162.s5.p4$Colestipol$DB00375$drug$Hydrochlorothiazide$DB00999$true$mechanism$drug$Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
DDI-DrugBank.d165.s10.p0$Itraconazole$DB01167$drug$Cisapride$DB00604$true$advise$drug$therefore concomitant administration of Itraconazole with cisapride is contraindicated.
DDI-DrugBank.d165.s11.p0$Itraconazole$DB01167$drug$Midazolam$DB00683$true$mechanism$drug$Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d165.s11.p1$Itraconazole$DB01167$drug$Triazolam$DB00897$true$mechanism$drug$Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d165.s15.p0$Itraconazole$DB01167$drug$Cyclosporine$DB00091$true$mechanism$drug$Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s15.p1$Itraconazole$DB01167$drug$Tacrolimus$DB00864$true$mechanism$drug$Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s15.p2$Itraconazole$DB01167$drug$Digoxin$DB00390$true$mechanism$drug$Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s16.p2$Cyclosporine$DB00091$drug$Itraconazole$DB01167$true$advise$drug$Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s16.p4$Tacrolimus$DB00864$drug$Itraconazole$DB01167$true$advise$drug$Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s16.p5$Digoxin$DB00390$drug$Itraconazole$DB01167$true$advise$drug$Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s18.p0$Itraconazole$DB01167$drug$Phenytoin$DB00252$true$mechanism$drug$When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
DDI-DrugBank.d165.s20.p0$Itraconazole$DB01167$drug$Phenytoin$DB00252$true$mechanism$drug$Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
DDI-DrugBank.d165.s21.p0$Phenytoin$DB00252$drug$Itraconazole$DB01167$true$advise$drug$therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
DDI-DrugBank.d165.s25.p2$Itraconazole$DB01167$drug$Isoniazid$DB00951$true$advise$drug$Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
DDI-DrugBank.d165.s28.p0$Itraconazole$DB01167$drug$Quinidine$DB00908$true$effect$drug$Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
DDI-DrugBank.d165.s3.p0$Terfenadine$DB00342$drug$Itraconazole$DB01167$true$mechanism$drug$Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
DDI-DrugBank.d165.s4.p4$Ketoconazole$DB01026$drug$Astemizole$DB00637$true$mechanism$drug$Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
DDI-DrugBank.d165.s5.p1$Itraconazole$DB01167$drug$Astemizole$DB00637$true$mechanism$drug$In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
DDI-DrugBank.d165.s6.p5$Astemizole$DB00637$drug$Itraconazole$DB01167$true$advise$drug$Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
DDI-DrugBank.d165.s7.p0$Ketoconazole$DB01026$drug$Cisapride$DB00604$true$mechanism$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
DDI-DrugBank.d165.s8.p0$Ketoconazole$DB01026$drug$Cisapride$DB00604$true$effect$drug$Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d165.s9.p0$Itraconazole$DB01167$drug$Cisapride$DB00604$true$mechanism$drug$In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
DDI-DrugBank.d166.s2.p0$Ethionamide$DB00609$drug$Cycloserine$DB00260$true$effect$drug$In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
DDI-DrugBank.d170.s2.p0$Fentanyl$DB00813$drug$Ritonavir$DB00503$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p1$Fentanyl$DB00813$drug$Ketoconazole$DB01026$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p2$Fentanyl$DB00813$drug$Itraconazole$DB01167$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p3$Fentanyl$DB00813$drug$Troleandomycin$DB01361$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p4$Fentanyl$DB00813$drug$Clarithromycin$DB01211$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p5$Fentanyl$DB00813$drug$Nelfinavir$DB00220$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s3.p1$Diltiazem$DB00343$drug$Fentanyl$DB00813$true$mechanism$drug$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DDI-DrugBank.d170.s3.p3$Erythromycin$DB00199$drug$Fentanyl$DB00813$true$mechanism$drug$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DDI-DrugBank.d172.s16.p2$Fluconazole$DB00196$drug$Celecoxib$DB00482$true$mechanism$drug$Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
DDI-DrugBank.d172.s17.p0$Celecoxib$DB00482$drug$Fluconazole$DB00196$true$mechanism$drug$This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
DDI-DrugBank.d172.s6.p0$Celecoxib$DB00482$drug$Fluconazole$DB00196$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DDI-DrugBank.d172.s6.p1$Celecoxib$DB00482$drug$Lithium$DB01356$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DDI-DrugBank.d174.s1.p0$Nabumetone$DB00461$drug$Warfarin$DB00682$true$advise$drug$Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
DDI-DrugBank.d175.s16.p0$Indomethacin$DB00328$drug$Captopril$DB01197$true$effect$drug$Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
DDI-DrugBank.d175.s6.p1$Nitroglycerin$DB00727$drug$Captopril$DB01197$true$advise$drug$therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
DDI-DrugBank.d176.s9.p19$Aluminum hydroxide$DB06723$drug$Fosinopril$DB00492$true$mechanism$drug$Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d178.s7.p0$Glyburide$DB01016$drug$Ciprofloxacin$DB00537$true$int$drug$A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
DDI-DrugBank.d179.s1.p0$Sulfapyridine$DB00891$drug$Acetaminophen$DB00316$true$int$drug$Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
DDI-DrugBank.d179.s38.p7$Methotrexate$DB00563$drug$Sulfapyridine$DB00891$true$effect$drug$- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
DDI-DrugBank.d179.s39.p5$Methyldopa$DB00968$drug$Sulfapyridine$DB00891$true$effect$drug$- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s40.p7$Phenytoin$DB00252$drug$Sulfapyridine$DB00891$true$effect$drug$- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
DDI-DrugBank.d18.s1.p35$Scopolamine$DB00747$drug$Lorazepam$DB00186$true$effect$drug$Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d185.s6.p1$Dapsone$DB00250$drug$Pyrimethamine$DB00205$true$effect$drug$With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d187.s11.p0$Isoniazid$DB00951$drug$Theophylline$DB00277$true$mechanism$drug$Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
DDI-DrugBank.d187.s2.p2$Acetaminophen$DB00316$drug$Isoniazid$DB00951$true$effect$drug$Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
DDI-DrugBank.d187.s3.p0$Isoniazid$DB00951$drug$Acetaminophen$DB00316$true$effect$drug$It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
DDI-DrugBank.d187.s5.p0$Isoniazid$DB00951$drug$Acetaminophen$DB00316$true$mechanism$drug$Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
DDI-DrugBank.d187.s7.p15$Carbamazepine$DB00564$drug$Isoniazid$DB00951$true$advise$drug$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DDI-DrugBank.d187.s7.p6$Isoniazid$DB00951$drug$Carbamazepine$DB00564$true$mechanism$drug$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DDI-DrugBank.d187.s8.p2$Ketoconazole$DB01026$drug$Isoniazid$DB00951$true$int$drug$Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
DDI-DrugBank.d187.s9.p2$Isoniazid$DB00951$drug$Phenytoin$DB00252$true$mechanism$drug$Phenytoin: Isoniazid may increase serum levels of phenytoin.
DDI-DrugBank.d188.s0.p5$Cimetidine$DB00501$drug$Altretamine$DB00488$true$mechanism$drug$Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
DDI-DrugBank.d188.s2.p1$Pyridoxine$DB00165$drug$Cisplatin$DB00515$true$advise$drug$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
DDI-DrugBank.d19.s1.p0$Disulfiram$DB00822$drug$Phenytoin$DB00252$true$advise$drug$DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DDI-DrugBank.d19.s2.p3$Disulfiram$DB00822$drug$Phenytoin$DB00252$true$effect$drug$SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
DDI-DrugBank.d19.s7.p0$Isoniazid$DB00951$drug$Disulfiram$DB00822$true$advise$drug$Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
DDI-DrugBank.d195.s7.p0$Tamoxifen$DB00675$drug$Anastrozole$DB01217$true$advise$drug$Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
DDI-DrugBank.d195.s8.p0$Anastrozole$DB01217$drug$Tamoxifen$DB00675$true$mechanism$drug$Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
DDI-DrugBank.d196.s6.p7$Ribavirin$DB00811$drug$Stavudine$DB00649$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DDI-DrugBank.d196.s6.p8$Ribavirin$DB00811$drug$Zidovudine$DB00495$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DDI-DrugBank.d198.s10.p5$Indinavir$DB00224$drug$Vardenafil$DB00862$true$mechanism$drug$HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
DDI-DrugBank.d198.s11.p0$Vardenafil$DB00862$drug$Indinavir$DB00224$true$advise$drug$It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
DDI-DrugBank.d198.s12.p0$Ritonavir$DB00503$drug$Vardenafil$DB00862$true$mechanism$drug$Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
DDI-DrugBank.d198.s13.p0$Vardenafil$DB00862$drug$Ritonavir$DB00503$true$mechanism$drug$The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
DDI-DrugBank.d198.s14.p0$Ritonavir$DB00503$drug$Vardenafil$DB00862$true$mechanism$drug$Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
DDI-DrugBank.d198.s15.p0$Vardenafil$DB00862$drug$Ritonavir$DB00503$true$advise$drug$Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
DDI-DrugBank.d198.s27.p0$Nifedipine$DB01115$drug$Vardenafil$DB00862$true$effect$drug$In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
DDI-DrugBank.d198.s28.p2$Vardenafil$DB00862$drug$Terazosin$DB01162$true$effect$drug$Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
DDI-DrugBank.d198.s29.p0$Vardenafil$DB00862$drug$Terazosin$DB01162$true$effect$drug$With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s30.p0$Vardenafil$DB00862$drug$Terazosin$DB01162$true$effect$drug$With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s31.p0$Vardenafil$DB00862$drug$Terazosin$DB01162$true$effect$drug$When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s32.p2$Vardenafil$DB00862$drug$Tamsulosin$DB00706$true$effect$drug$In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s33.p0$Vardenafil$DB00862$drug$Tamsulosin$DB00706$true$effect$drug$Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s36.p7$Vardenafil$DB00862$drug$Ritonavir$DB00503$true$mechanism$drug$Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
DDI-DrugBank.d198.s37.p0$Vardenafil$DB00862$drug$Indinavir$DB00224$true$mechanism$drug$Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
DDI-DrugBank.d198.s5.p0$Erythromycin$DB00199$drug$Vardenafil$DB00862$true$mechanism$drug$Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
DDI-DrugBank.d198.s6.p0$Vardenafil$DB00862$drug$Erythromycin$DB00199$true$advise$drug$It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
DDI-DrugBank.d198.s7.p0$Ketoconazole$DB01026$drug$Vardenafil$DB00862$true$mechanism$drug$Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
DDI-DrugBank.d198.s8.p0$Vardenafil$DB00862$drug$Ketoconazole$DB01026$true$advise$drug$A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
DDI-DrugBank.d198.s9.p2$Vardenafil$DB00862$drug$Ketoconazole$DB01026$true$advise$drug$Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
DDI-DrugBank.d20.s3.p0$Eplerenone$DB00700$drug$Erythromycin$DB00199$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3.p1$Eplerenone$DB00700$drug$Verapamil$DB00661$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3.p2$Eplerenone$DB00700$drug$Saquinavir$DB01232$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3.p3$Eplerenone$DB00700$drug$Fluconazole$DB00196$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d205.s0.p15$Ethosuximide$DB00593$drug$Phenytoin$DB00252$true$mechanism$drug$Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d205.s0.p20$Valproic Acid$DB00313$drug$Ethosuximide$DB00593$true$mechanism$drug$Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d207.s4.p1$Ketoconazole$DB01026$drug$Gefitinib$DB00317$true$mechanism$drug$Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d207.s4.p2$Ketoconazole$DB01026$drug$Gefitinib$DB00317$true$mechanism$drug$Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d207.s4.p3$Itraconazole$DB01167$drug$Gefitinib$DB00317$true$mechanism$drug$Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d207.s4.p4$Itraconazole$DB01167$drug$Gefitinib$DB00317$true$mechanism$drug$Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d208.s0.p3$Benzthiazide$DB00562$drug$Lithium$DB01356$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0.p4$Benzthiazide$DB00562$drug$Norepinephrine$DB00368$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0.p7$Benzthiazide$DB00562$drug$Ibuprofen$DB01050$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d210.s10.p2$Cimetidine$DB00501$drug$Rofecoxib$DB00533$true$mechanism$drug$Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
DDI-DrugBank.d210.s21.p3$Methotrexate$DB00563$drug$Rofecoxib$DB00533$true$mechanism$drug$At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
DDI-DrugBank.d210.s32.p0$Warfarin$DB00682$drug$Rofecoxib$DB00533$true$effect$drug$In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
DDI-DrugBank.d211.s5.p0$Probenecid$DB01032$drug$Ampicillin$DB00415$true$mechanism$drug$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
DDI-DrugBank.d216.s0.p3$Eszopiclone$DB00402$drug$Ethanol$DB00898$true$effect$drug$CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
DDI-DrugBank.d216.s10.p2$Zopiclone$DB01198$drug$Rifampicin$DB01045$true$mechanism$drug$Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
DDI-DrugBank.d216.s3.p2$Eszopiclone$DB00402$drug$Olanzapine$DB00334$true$effect$drug$Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
DDI-DrugBank.d216.s7.p0$Eszopiclone$DB00402$drug$Ketoconazole$DB01026$true$mechanism$drug$The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
DDI-DrugBank.d217.s1.p2$Norfloxacin$DB01059$drug$Theophylline$DB00277$true$effect$drug$There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
DDI-DrugBank.d217.s10.p2$Nitrofurantoin$DB00698$drug$Norfloxacin$DB01059$true$effect$drug$The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
DDI-DrugBank.d217.s11.p13$Zinc$DB01593$drug$Norfloxacin$DB01059$true$advise$drug$Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s11.p18$Sucralfate$DB00364$drug$Norfloxacin$DB01059$true$advise$drug$Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s11.p9$Iron$DB01592$drug$Norfloxacin$DB01059$true$advise$drug$Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s12.p3$Didanosine$DB00900$drug$Norfloxacin$DB01059$true$advise$drug$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s3.p2$Cyclosporine$DB00091$drug$Norfloxacin$DB01059$true$mechanism$drug$Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
DDI-DrugBank.d217.s5.p4$Norfloxacin$DB01059$drug$Warfarin$DB00682$true$effect$drug$Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d217.s7.p3$Norfloxacin$DB01059$drug$Glyburide$DB01016$true$effect$drug$The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d217.s9.p2$Probenecid$DB01032$drug$Norfloxacin$DB01059$true$mechanism$drug$Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
DDI-DrugBank.d219.s19.p2$Phenylbutazone$DB00812$drug$Etodolac$DB00749$true$mechanism$drug$Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
DDI-DrugBank.d219.s20.p0$Etodolac$DB00749$drug$Phenylbutazone$DB00812$true$advise$drug$Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
DDI-DrugBank.d219.s23.p1$Warfarin$DB00682$drug$Etodolac$DB00749$true$mechanism$drug$Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
DDI-DrugBank.d219.s26.p0$Etodolac$DB00749$drug$Warfarin$DB00682$true$effect$drug$However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
DDI-DrugBank.d22.s0.p0$Aminosalicylic Acid$DB00233$drug$Digoxin$DB00390$true$mechanism$drug$Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
DDI-DrugBank.d22.s1.p0$Digoxin$DB00390$drug$Aminosalicylic Acid$DB00233$true$advise$drug$In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
DDI-DrugBank.d220.s11.p13$Carbamazepine$DB00564$drug$Mefloquine$DB00358$true$effect$drug$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s11.p16$Phenobarbital$DB01174$drug$Mefloquine$DB00358$true$effect$drug$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s11.p18$Phenytoin$DB00252$drug$Mefloquine$DB00358$true$effect$drug$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s11.p9$Valproic Acid$DB00313$drug$Mefloquine$DB00358$true$effect$drug$In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s4.p0$Halofantrine$DB01218$drug$Mefloquine$DB00358$true$advise$drug$Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
DDI-DrugBank.d220.s5.p0$Mefloquine$DB00358$drug$Quinine$DB00468$true$effect$drug$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d220.s5.p1$Mefloquine$DB00358$drug$Quinidine$DB00908$true$effect$drug$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d220.s5.p2$Mefloquine$DB00358$drug$Chloroquine$DB00608$true$effect$drug$Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d222.s0.p0$Atropine$DB00572$drug$Pralidoxime$DB00733$true$effect$drug$When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
DDI-DrugBank.d222.s0.p9$Pralidoxime$DB00733$drug$Atropine$DB00572$true$effect$drug$When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
DDI-DrugBank.d222.s1.p0$Atropine$DB00572$drug$Pralidoxime$DB00733$true$advise$drug$The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
DDI-DrugBank.d223.s16.p2$Quinidine$DB00908$drug$Doxepin$DB01142$true$mechanism$drug$Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DDI-DrugBank.d223.s28.p2$Tolazamide$DB00839$drug$Doxepin$DB01142$true$effect$drug$Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
DDI-DrugBank.d225.s11.p0$Fluconazole$DB00196$drug$Glipizide$DB01067$true$int$drug$The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
DDI-DrugBank.d225.s13.p0$Glipizide$DB01067$drug$Fluconazole$DB00196$true$mechanism$drug$The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
DDI-DrugBank.d226.s4.p1$Adenosine$DB00640$drug$Caffeine$DB00201$true$effect$drug$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d226.s4.p2$Adenosine$DB00640$drug$Theophylline$DB00277$true$effect$drug$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d226.s6.p0$Adenosine$DB00640$drug$Dipyridamole$DB00975$true$effect$drug$Adenosine effects are potentiated by dipyridamole.
DDI-DrugBank.d226.s7.p0$Adenosine$DB00640$drug$Dipyridamole$DB00975$true$effect$drug$Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
DDI-DrugBank.d226.s9.p0$Adenosine$DB00640$drug$Carbamazepine$DB00564$true$effect$drug$As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
DDI-DrugBank.d231.s10.p0$Sucralfate$DB00364$drug$Furosemide$DB00695$true$effect$drug$Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
DDI-DrugBank.d231.s12.p0$Furosemide$DB00695$drug$Sucralfate$DB00364$true$advise$drug$The intake of furosemide and sucralfate should be separated by at least two hours.
DDI-DrugBank.d231.s13.p0$Furosemide$DB00695$drug$Acetylsalicylic acid$DB00945$true$effect$drug$Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
DDI-DrugBank.d231.s15.p0$Indomethacin$DB00328$drug$Furosemide$DB00695$true$effect$drug$Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
DDI-DrugBank.d231.s17.p0$Indomethacin$DB00328$drug$Furosemide$DB00695$true$advise$drug$Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
DDI-DrugBank.d231.s2.p0$Furosemide$DB00695$drug$Ethacrynic acid$DB00903$true$advise$drug$Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
DDI-DrugBank.d231.s4.p0$Furosemide$DB00695$drug$Tubocurarine$DB01199$true$effect$drug$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DDI-DrugBank.d231.s4.p1$Furosemide$DB00695$drug$Succinylcholine$DB00202$true$effect$drug$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DDI-DrugBank.d231.s8.p0$Furosemide$DB00695$drug$Norepinephrine$DB00368$true$effect$drug$Furosemide may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d233.s0.p2$Azathioprine$DB00993$drug$Allopurinol$DB00437$true$mechanism$drug$Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
DDI-DrugBank.d233.s1.p0$Azathioprine$DB00993$drug$Allopurinol$DB00437$true$advise$drug$Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
DDI-DrugBank.d236.s10.p5$Furazolidone$DB00614$drug$Amphetamine$DB00182$true$mechanism$group$MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d236.s5.p1$Acetazolamide$DB00819$drug$Amphetamine$DB00182$true$mechanism$drug$Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
DDI-DrugBank.d237.s10.p4$Cimetidine$DB00501$drug$Cisapride$DB00604$true$mechanism$drug$H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
DDI-DrugBank.d237.s11.p1$Cimetidine$DB00501$drug$Cisapride$DB00604$true$mechanism$drug$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DDI-DrugBank.d237.s11.p2$Ranitidine$DB00863$drug$Cisapride$DB00604$true$mechanism$drug$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DDI-DrugBank.d237.s12.p5$Indinavir$DB00224$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s12.p7$Ritonavir$DB00503$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s14.p1$Cisapride$DB00604$drug$Quinidine$DB00908$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s14.p2$Cisapride$DB00604$drug$Procainamide$DB01035$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s14.p3$Cisapride$DB00604$drug$Sotalol$DB00489$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s2.p10$Erythromycin$DB00199$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s2.p12$Troleandomycin$DB01361$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s2.p7$Clarithromycin$DB01211$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s3.p9$Dicyclomine$DB00804$drug$Cisapride$DB00604$true$effect$drug$Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DDI-DrugBank.d237.s6.p3$Nefazodone$DB01149$drug$Cisapride$DB00604$true$mechanism$drug$Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7.p10$Itraconazole$DB01167$drug$Cisapride$DB00604$true$mechanism$drug$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7.p12$Ketoconazole$DB01026$drug$Cisapride$DB00604$true$mechanism$drug$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7.p7$Fluconazole$DB00196$drug$Cisapride$DB00604$true$mechanism$drug$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s8.p0$Ketoconazole$DB01026$drug$Cisapride$DB00604$true$mechanism$drug$Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
DDI-DrugBank.d237.s9.p0$Cisapride$DB00604$drug$Ketoconazole$DB01026$true$effect$drug$A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d240.s2.p0$Ethopropazine$DB00392$drug$Chlorpromazine$DB00477$true$mechanism$drug$Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
DDI-DrugBank.d246.s12.p0$Butorphanol$DB00611$drug$Erythromycin$DB00199$true$advise$drug$It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
DDI-DrugBank.d247.s5.p2$Epinephrine$DB00668$drug$Halothane$DB01159$true$effect$drug$Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DDI-DrugBank.d247.s9.p0$Epinephrine$DB00668$drug$Guanethidine$DB01170$true$effect$drug$Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
DDI-DrugBank.d249.s17.p2$Phenobarbital$DB01174$drug$Diclofenac$DB00586$true$effect$drug$Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
DDI-DrugBank.d249.s18.p1$Diclofenac$DB00586$drug$Tolbutamide$DB01124$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s18.p2$Diclofenac$DB00586$drug$Prednisolone$DB00860$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s18.p3$Diclofenac$DB00586$drug$Warfarin$DB00682$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s2.p7$Diclofenac$DB00586$drug$Warfarin$DB00682$true$advise$drug$Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
DDI-DrugBank.d249.s4.p0$Diclofenac$DB00586$drug$Digoxin$DB00390$true$mechanism$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s4.p1$Diclofenac$DB00586$drug$Methotrexate$DB00563$true$mechanism$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s4.p2$Diclofenac$DB00586$drug$Cyclosporine$DB00091$true$effect$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s5.p2$Diclofenac$DB00586$drug$Digoxin$DB00390$true$effect$drug$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5.p3$Diclofenac$DB00586$drug$Methotrexate$DB00563$true$effect$drug$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5.p4$Diclofenac$DB00586$drug$Cyclosporine$DB00091$true$effect$drug$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s8.p3$Diclofenac$DB00586$drug$Lithium$DB01356$true$mechanism$drug$Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
DDI-DrugBank.d249.s8.p4$Diclofenac$DB00586$drug$Lithium$DB01356$true$mechanism$drug$Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
DDI-DrugBank.d249.s9.p0$Diclofenac$DB00586$drug$Lithium$DB01356$true$effect$drug$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
DDI-DrugBank.d256.s2.p0$Clindamycin$DB01190$drug$Erythromycin$DB00199$true$effect$drug$Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
DDI-DrugBank.d258.s4.p0$Erythromycin$DB00199$drug$Loratadine$DB00455$true$mechanism$drug$Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
DDI-DrugBank.d260.s0.p15$Probenecid$DB01032$drug$Acetaminophen$DB00316$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p18$Probenecid$DB01032$drug$Aminosalicylic Acid$DB00233$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p21$Probenecid$DB01032$drug$Bumetanide$DB00887$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p22$Probenecid$DB01032$drug$Clofibrate$DB00636$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p23$Probenecid$DB01032$drug$Methotrexate$DB00563$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p24$Probenecid$DB01032$drug$Famotidine$DB00927$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p25$Probenecid$DB01032$drug$Furosemide$DB00695$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p27$Probenecid$DB01032$drug$Theophylline$DB00277$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p28$Probenecid$DB01032$drug$Zidovudine$DB00495$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s2.p0$Zidovudine$DB00495$drug$Probenecid$DB01032$true$advise$drug$Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
DDI-DrugBank.d263.s18.p24$Foscarnet$DB00529$drug$Zalcitabine$DB00943$true$mechanism$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s20.p10$Probenecid$DB01032$drug$Zalcitabine$DB00943$true$mechanism$drug$Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
DDI-DrugBank.d263.s20.p12$Cimetidine$DB00501$drug$Zalcitabine$DB00943$true$mechanism$drug$Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
DDI-DrugBank.d263.s23.p0$Zalcitabine$DB00943$drug$Magnesium$DB01378$true$advise$drug$The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
DDI-DrugBank.d263.s24.p2$Zalcitabine$DB00943$drug$Metoclopramide$DB01233$true$mechanism$drug$Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
DDI-DrugBank.d263.s25.p2$Doxorubicin$DB00997$drug$Zalcitabine$DB00943$true$effect$drug$Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
DDI-DrugBank.d263.s3.p2$Lamivudine$DB00709$drug$Zalcitabine$DB00943$true$effect$drug$Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
DDI-DrugBank.d263.s5.p0$Zalcitabine$DB00943$drug$Lamivudine$DB00709$true$effect$drug$Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
DDI-DrugBank.d263.s7.p0$Zalcitabine$DB00943$drug$Lamivudine$DB00709$true$effect$drug$These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
DDI-DrugBank.d263.s9.p0$Zalcitabine$DB00943$drug$Lamivudine$DB00709$true$advise$drug$Concomitant use of zalcitabine and lamivudine is not recommended.
DDI-DrugBank.d265.s7.p0$Chlorthalidone$DB00310$drug$Tubocurarine$DB01199$true$effect$drug$Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
DDI-DrugBank.d265.s8.p0$Chlorthalidone$DB00310$drug$Norepinephrine$DB00368$true$effect$drug$Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d269.s1.p14$Quinidine$DB00908$drug$Carvedilol$DB01136$true$effect$drug$poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s1.p17$Fluoxetine$DB00472$drug$Carvedilol$DB01136$true$effect$drug$poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s1.p19$Paroxetine$DB00715$drug$Carvedilol$DB01136$true$effect$drug$poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s1.p20$Propafenone$DB01182$drug$Carvedilol$DB01136$true$effect$drug$poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s10.p0$Cyclosporine$DB00091$drug$Carvedilol$DB01136$true$advise$drug$Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
DDI-DrugBank.d269.s10.p2$Carvedilol$DB01136$drug$Cyclosporine$DB00091$true$advise$drug$Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
DDI-DrugBank.d269.s11.p5$Digoxin$DB00390$drug$Carvedilol$DB01136$true$mechanism$drug$Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
DDI-DrugBank.d269.s7.p2$Cyclosporine$DB00091$drug$Carvedilol$DB01136$true$mechanism$drug$Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
DDI-DrugBank.d270.s11.p0$Warfarin$DB00682$drug$Nevirapine$DB00238$true$advise$drug$When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
DDI-DrugBank.d270.s18.p0$Clarithromycin$DB01211$drug$Nevirapine$DB00238$true$mechanism$drug$Clarithromycin exposure was significantly decreased by nevirapine;
DDI-DrugBank.d270.s36.p0$Nevirapine$DB00238$drug$Ketoconazole$DB01026$true$advise$drug$Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
DDI-DrugBank.d270.s39.p1$Lopinavir$DB01601$drug$Nevirapine$DB00238$true$advise$drug$A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
DDI-DrugBank.d270.s39.p2$Ritonavir$DB00503$drug$Nevirapine$DB00238$true$advise$drug$A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
DDI-DrugBank.d270.s42.p7$Methadone$DB00333$drug$Nevirapine$DB00238$true$advise$drug$Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
DDI-DrugBank.d270.s58.p0$Nevirapine$DB00238$drug$Methadone$DB00333$true$effect$drug$aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
DDI-DrugBank.d270.s9.p1$Nevirapine$DB00238$drug$Warfarin$DB00682$true$int$drug$The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
DDI-DrugBank.d274.s2.p0$Dobutamine$DB00841$drug$Nitroprusside$DB00325$true$effect$drug$Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
DDI-DrugBank.d276.s2.p4$Probenecid$DB01032$drug$Nitrofurantoin$DB00698$true$mechanism$drug$Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d276.s2.p5$Sulfinpyrazone$DB01138$drug$Nitrofurantoin$DB00698$true$mechanism$drug$Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d277.s10.p12$Tiagabine$DB00906$drug$Carbamazepine$DB00564$true$mechanism$drug$Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
DDI-DrugBank.d277.s11.p3$Tiagabine$DB00906$drug$Phenytoin$DB00252$true$mechanism$drug$Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
DDI-DrugBank.d277.s12.p10$Tiagabine$DB00906$drug$Primidone$DB00794$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DDI-DrugBank.d277.s12.p9$Tiagabine$DB00906$drug$Phenobarbital$DB01174$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DDI-DrugBank.d277.s23.p1$Ethanol$DB00898$drug$Tiagabine$DB00906$true$advise$drug$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DDI-DrugBank.d277.s23.p2$Triazolam$DB00897$drug$Tiagabine$DB00906$true$advise$drug$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DDI-DrugBank.d283.s13.p1$Fenofibrate$DB01039$drug$Pravastatin$DB00175$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
DDI-DrugBank.d283.s15.p1$Fenofibrate$DB01039$drug$Atorvastatin$DB01076$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
DDI-DrugBank.d286.s0.p2$Ethoxzolamide$DB00311$drug$Procainamide$DB01035$true$effect$drug$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d286.s0.p3$Ethoxzolamide$DB00311$drug$Quinidine$DB00908$true$effect$drug$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d286.s2.p1$Ethoxzolamide$DB00311$drug$Amphotericin B$DB00681$true$effect$drug$Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
DDI-DrugBank.d288.s5.p5$Paclitaxel$DB01229$drug$Doxorubicin$DB00997$true$mechanism$drug$Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
DDI-DrugBank.d289.s15.p0$Tacrolimus$DB00864$drug$Bosentan$DB00559$true$mechanism$drug$Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
DDI-DrugBank.d289.s16.p0$Tacrolimus$DB00864$drug$Bosentan$DB00559$true$advise$drug$Caution should be exercised if tacrolimus and bosentan are used together.
DDI-DrugBank.d289.s19.p0$Bosentan$DB00559$drug$Glyburide$DB01016$true$mechanism$drug$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
DDI-DrugBank.d289.s23.p3$Bosentan$DB00559$drug$Ketoconazole$DB01026$true$mechanism$drug$Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
DDI-DrugBank.d289.s25.p5$Bosentan$DB00559$drug$Simvastatin$DB00641$true$mechanism$drug$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
DDI-DrugBank.d289.s27.p1$Bosentan$DB00559$drug$Lovastatin$DB00227$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d289.s27.p2$Bosentan$DB00559$drug$Atorvastatin$DB01076$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d29.s12.p0$Esomeprazole$DB00736$drug$Ketoconazole$DB01026$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d29.s12.p1$Esomeprazole$DB00736$drug$Iron$DB01592$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d29.s12.p2$Esomeprazole$DB00736$drug$Digoxin$DB00390$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d29.s14.p0$Clarithromycin$DB01211$drug$Pimozide$DB01100$true$advise$drug$Concomitant administration of clarithromycin with pimozide is contraindicated.
DDI-DrugBank.d29.s8.p0$Esomeprazole$DB00736$drug$Diazepam$DB00829$true$mechanism$drug$Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
DDI-DrugBank.d298.s0.p0$Cyclopentolate$DB00979$drug$Carbachol$DB00411$true$effect$drug$Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DDI-DrugBank.d298.s0.p1$Cyclopentolate$DB00979$drug$Pilocarpine$DB01085$true$effect$drug$Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DDI-DrugBank.d299.s10.p0$Almotriptan$DB00918$drug$Ketoconazole$DB01026$true$mechanism$drug$Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
DDI-DrugBank.d299.s11.p11$Ritonavir$DB00503$drug$Almotriptan$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s11.p13$Erythromycin$DB00199$drug$Almotriptan$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s11.p8$Itraconazole$DB01167$drug$Almotriptan$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s2.p2$Moclobemide$DB01171$drug$Almotriptan$DB00918$true$mechanism$drug$Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
DDI-DrugBank.d299.s8.p3$Almotriptan$DB00918$drug$Verapamil$DB00661$true$mechanism$drug$Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
DDI-DrugBank.d30.s4.p0$Fluconazole$DB00196$drug$Losartan$DB00678$true$mechanism$drug$Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
DDI-DrugBank.d30.s9.p4$Losartan$DB00678$drug$Indomethacin$DB00328$true$effect$drug$As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
DDI-DrugBank.d303.s0.p4$Cephalexin$DB00567$drug$Metformin$DB00331$true$mechanism$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
DDI-DrugBank.d303.s2.p0$Cephalexin$DB00567$drug$Metformin$DB00331$true$mechanism$drug$Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
DDI-DrugBank.d303.s3.p2$Cephalexin$DB00567$drug$Metformin$DB00331$true$advise$drug$Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
DDI-DrugBank.d303.s4.p5$Cephalexin$DB00567$drug$Probenecid$DB01032$true$mechanism$drug$Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
DDI-DrugBank.d305.s7.p0$Dantrolene$DB01219$drug$Vecuronium$DB01339$true$effect$drug$Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
DDI-DrugBank.d31.s2.p0$Diazoxide$DB01119$drug$Hydralazine$DB01275$true$effect$drug$Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
DDI-DrugBank.d31.s5.p0$Propranolol$DB00571$drug$Hydralazine$DB01275$true$mechanism$drug$Propranolol increases hydralazines serum concentrations.
DDI-DrugBank.d310.s3.p2$Cimetidine$DB00501$drug$Nimodipine$DB00393$true$mechanism$drug$A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
DDI-DrugBank.d314.s2.p0$Amphotericin B$DB00681$drug$Hydrocortisone$DB00741$true$effect$drug$In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
DDI-DrugBank.d314.s27.p2$Phenytoin$DB00252$drug$Dexamethasone$DB01234$true$mechanism$drug$Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
DDI-DrugBank.d315.s0.p3$Digoxin$DB00390$drug$Conivaptan$DB00872$true$mechanism$drug$Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
DDI-DrugBank.d316.s14.p6$Felodipine$DB01023$drug$Phenytoin$DB00252$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d316.s14.p7$Felodipine$DB01023$drug$Carbamazepine$DB00564$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d316.s14.p8$Felodipine$DB01023$drug$Phenobarbital$DB01174$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d318.s12.p4$Amphotericin B$DB00681$drug$Tubocurarine$DB01199$true$effect$drug$Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
DDI-DrugBank.d318.s2.p4$Corticotropin$DB01285$drug$Amphotericin B$DB00681$true$effect$drug$Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
DDI-DrugBank.d318.s7.p2$Amphotericin B$DB00681$drug$Flucytosine$DB01099$true$effect$drug$Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
DDI-DrugBank.d32.s7.p0$Ranitidine$DB00863$drug$Ceftibuten$DB01415$true$mechanism$drug$however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DDI-DrugBank.d32.s7.p1$Ranitidine$DB00863$drug$Ceftibuten$DB01415$true$mechanism$drug$however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DDI-DrugBank.d320.s3.p0$Levobupivacaine$DB01002$drug$Phenytoin$DB00252$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d320.s3.p1$Levobupivacaine$DB01002$drug$Phenobarbital$DB01174$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d320.s3.p3$Levobupivacaine$DB01002$drug$Ketoconazole$DB01026$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d321.s0.p5$Dexamethasone$DB01234$drug$Albendazole$DB00518$true$mechanism$drug$Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
DDI-DrugBank.d322.s0.p2$Amantadine$DB00915$drug$Clidinium$DB00771$true$effect$drug$Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
DDI-DrugBank.d322.s1.p2$Clidinium$DB00771$drug$Ketoconazole$DB01026$true$effect$drug$Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
DDI-DrugBank.d324.s12.p3$Zaleplon$DB00962$drug$Promethazine$DB01069$true$mechanism$drug$Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
DDI-DrugBank.d324.s20.p0$Zaleplon$DB00962$drug$Erythromycin$DB00199$true$mechanism$drug$Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
DDI-DrugBank.d324.s22.p0$Ketoconazole$DB01026$drug$Zaleplon$DB00962$true$mechanism$drug$Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
DDI-DrugBank.d324.s28.p2$Cimetidine$DB00501$drug$Zaleplon$DB00962$true$mechanism$drug$Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
DDI-DrugBank.d325.s11.p0$Dopamine$DB00988$drug$Propranolol$DB00571$true$effect$drug$It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
DDI-DrugBank.d325.s4.p1$Dopamine$DB00988$drug$Propranolol$DB00571$true$effect$drug$Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d325.s4.p2$Dopamine$DB00988$drug$Metoprolol$DB00264$true$effect$drug$Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d325.s7.p4$Haloperidol$DB00502$drug$Dopamine$DB00988$true$effect$drug$Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DDI-DrugBank.d328.s12.p5$Valdecoxib$DB00580$drug$Phenytoin$DB00252$true$mechanism$drug$Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
DDI-DrugBank.d328.s13.p0$Valdecoxib$DB00580$drug$Phenytoin$DB00252$true$advise$drug$Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
DDI-DrugBank.d328.s18.p0$Valdecoxib$DB00580$drug$Dextromethorphan$DB00514$true$mechanism$drug$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
DDI-DrugBank.d328.s19.p0$Dextromethorphan$DB00514$drug$Valdecoxib$DB00580$true$mechanism$drug$Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
DDI-DrugBank.d328.s20.p3$Valdecoxib$DB00580$drug$Lithium$DB01356$true$mechanism$drug$Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
DDI-DrugBank.d328.s24.p2$Valdecoxib$DB00580$drug$Warfarin$DB00682$true$effect$drug$Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DDI-DrugBank.d328.s28.p0$Valdecoxib$DB00580$drug$Ketoconazole$DB01026$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
DDI-DrugBank.d328.s28.p1$Valdecoxib$DB00580$drug$Fluconazole$DB00196$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
DDI-DrugBank.d328.s29.p0$Valdecoxib$DB00580$drug$Fluconazole$DB00196$true$mechanism$drug$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DDI-DrugBank.d328.s29.p1$Valdecoxib$DB00580$drug$Ketoconazole$DB01026$true$mechanism$drug$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DDI-DrugBank.d328.s33.p0$Valdecoxib$DB00580$drug$Glyburide$DB01016$true$mechanism$drug$Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
DDI-DrugBank.d328.s35.p2$Glyburide$DB01016$drug$Valdecoxib$DB00580$true$advise$drug$Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
DDI-DrugBank.d328.s39.p0$Valdecoxib$DB00580$drug$Omeprazole$DB00338$true$mechanism$drug$Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
DDI-DrugBank.d328.s48.p0$Diazepam$DB00829$drug$Valdecoxib$DB00580$true$mechanism$drug$Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
DDI-DrugBank.d328.s49.p2$Valdecoxib$DB00580$drug$Diazepam$DB00829$true$effect$drug$Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
DDI-DrugBank.d329.s0.p5$Probenecid$DB01032$drug$Ertapenem$DB00303$true$mechanism$drug$When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
DDI-DrugBank.d329.s1.p0$Ertapenem$DB00303$drug$Probenecid$DB01032$true$mechanism$drug$Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
DDI-DrugBank.d329.s3.p0$Probenecid$DB01032$drug$Ertapenem$DB00303$true$advise$drug$Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
DDI-DrugBank.d330.s2.p0$Neomycin$DB00994$drug$Penicillin V$DB00417$true$mechanism$drug$Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d330.s2.p2$Neomycin$DB00994$drug$Methotrexate$DB00563$true$mechanism$drug$Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d331.s3.p5$Lithium$DB01356$drug$Bumetanide$DB00887$true$advise$drug$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d331.s4.p2$Probenecid$DB01032$drug$Bumetanide$DB00887$true$effect$drug$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
DDI-DrugBank.d331.s5.p0$Probenecid$DB01032$drug$Bumetanide$DB00887$true$mechanism$drug$This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
DDI-DrugBank.d331.s6.p0$Probenecid$DB01032$drug$Bumetanide$DB00887$true$advise$drug$Thus, probenecid should not be administered concurrently with bumetanide.
DDI-DrugBank.d331.s7.p3$Indomethacin$DB00328$drug$Bumetanide$DB00887$true$mechanism$drug$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
DDI-DrugBank.d331.s7.p4$Indomethacin$DB00328$drug$Bumetanide$DB00887$true$effect$drug$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
DDI-DrugBank.d333.s3.p0$Clonazepam$DB01068$drug$Propantheline$DB00782$true$mechanism$drug$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DDI-DrugBank.d333.s3.p14$Clonazepam$DB01068$drug$Propantheline$DB00782$true$mechanism$drug$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DDI-DrugBank.d333.s5.p2$Phenytoin$DB00252$drug$Clonazepam$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d333.s5.p5$Carbamazepine$DB00564$drug$Clonazepam$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d333.s5.p7$Phenobarbital$DB01174$drug$Clonazepam$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d338.s4.p0$Estazolam$DB01215$drug$Carbamazepine$DB00564$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s4.p1$Estazolam$DB01215$drug$Phenytoin$DB00252$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s4.p4$Estazolam$DB01215$drug$Estazolam$DB01215$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s6.p0$Estazolam$DB01215$drug$Ketoconazole$DB01026$true$advise$drug$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DDI-DrugBank.d338.s6.p1$Estazolam$DB01215$drug$Itraconazole$DB01167$true$advise$drug$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DDI-DrugBank.d339.s2.p1$Warfarin$DB00682$drug$Cefixime$DB00671$true$effect$drug$Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
DDI-DrugBank.d340.s26.p0$Nelfinavir$DB00220$drug$Didanosine$DB00900$true$advise$drug$therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
DDI-DrugBank.d344.s0.p0$Calcium$DB01373$drug$L-Lysine$DB00123$true$mechanism$drug$Concomitant use of calcium supplements and L-lysine may increase calcium absorption
DDI-DrugBank.d347.s6.p2$Gemifloxacin$DB01155$drug$Magnesium$DB01378$true$mechanism$drug$The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
DDI-DrugBank.d350.s7.p0$Cyclosporine$DB00091$drug$Caspofungin$DB00520$true$mechanism$drug$In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
DDI-DrugBank.d351.s0.p7$Loracarbef$DB00447$drug$Probenecid$DB01032$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
DDI-DrugBank.d352.s3.p1$Diethylpropion$DB00937$drug$Guanethidine$DB01170$true$int$drug$conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DDI-DrugBank.d353.s0.p5$Acitretin$DB00459$drug$Ethanol$DB00898$true$mechanism$drug$Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
DDI-DrugBank.d353.s10.p3$Acitretin$DB00459$drug$Phenytoin$DB00252$true$mechanism$drug$Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
DDI-DrugBank.d353.s12.p8$Vitamin A$DB00162$group$Acitretin$DB00459$true$advise$drug$Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
DDI-DrugBank.d353.s8.p2$Methotrexate$DB00563$drug$Etretinate$DB00926$true$effect$drug$Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
DDI-DrugBank.d353.s9.p0$Methotrexate$DB00563$drug$Acitretin$DB00459$true$advise$drug$Consequently, the combination of methotrexate with acitretin is also contraindicated.
DDI-DrugBank.d354.s1.p0$Nitazoxanide$DB00507$drug$Warfarin$DB00682$true$mechanism$drug$Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
DDI-DrugBank.d357.s0.p25$Apomorphine$DB00714$drug$Ondansetron$DB00904$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p26$Apomorphine$DB00714$drug$Granisetron$DB00889$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p27$Apomorphine$DB00714$drug$Dolasetron$DB00757$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p28$Apomorphine$DB00714$drug$Palonosetron$DB00377$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p29$Apomorphine$DB00714$drug$Alosetron$DB00969$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p9$Apomorphine$DB00714$drug$Ondansetron$DB00904$true$effect$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d358.s1.p1$Omeprazole$DB00338$drug$Cilostazol$DB01166$true$mechanism$drug$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DDI-DrugBank.d358.s1.p2$Erythromycin$DB00199$drug$Cilostazol$DB01166$true$mechanism$drug$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DDI-DrugBank.d358.s2.p0$Cilostazol$DB01166$drug$Diltiazem$DB00343$true$mechanism$drug$Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
DDI-DrugBank.d362.s4.p0$Ciclesonide$DB01410$drug$Ketoconazole$DB01026$true$mechanism$drug$In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
DDI-DrugBank.d362.s5.p0$Ketoconazole$DB01026$drug$Ciclesonide$DB01410$true$advise$drug$Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
DDI-DrugBank.d364.s10.p0$Alosetron$DB00969$drug$Clarithromycin$DB01211$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10.p1$Alosetron$DB00969$drug$Telithromycin$DB00976$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10.p3$Alosetron$DB00969$drug$Voriconazole$DB00582$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10.p4$Alosetron$DB00969$drug$Itraconazole$DB01167$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s15.p0$Alosetron$DB00969$drug$Isoniazid$DB00951$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s15.p1$Alosetron$DB00969$drug$Procainamide$DB01035$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s15.p2$Alosetron$DB00969$drug$Hydralazine$DB01275$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s3.p0$Fluvoxamine$DB00176$drug$Alosetron$DB00969$true$mechanism$drug$Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
DDI-DrugBank.d364.s4.p0$Alosetron$DB00969$drug$Fluvoxamine$DB00176$true$advise$drug$Concomitant administration of alosetron and fluvoxamine is contraindicated.
DDI-DrugBank.d364.s5.p1$Alosetron$DB00969$drug$Cimetidine$DB00501$true$advise$drug$Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
DDI-DrugBank.d364.s8.p0$Ketoconazole$DB01026$drug$Alosetron$DB00969$true$mechanism$drug$Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
DDI-DrugBank.d364.s9.p0$Alosetron$DB00969$drug$Ketoconazole$DB01026$true$advise$drug$Caution should be used when alosetron and ketoconazole are administered concomitantly.
DDI-DrugBank.d365.s0.p2$L-Histidine$DB00117$drug$Medroxyprogesterone Acetate$DB00603$true$effect$drug$Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
DDI-DrugBank.d367.s4.p0$Doxazosin$DB00590$drug$Cimetidine$DB00501$true$mechanism$drug$In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
DDI-DrugBank.d368.s10.p0$Acetazolamide$DB00819$drug$Quinidine$DB00908$true$mechanism$drug$Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
DDI-DrugBank.d368.s12.p0$Acetazolamide$DB00819$drug$Lithium$DB01356$true$mechanism$drug$Acetazolamide increases lithium excretion and the lithium may be decreased.
DDI-DrugBank.d368.s13.p0$Acetazolamide$DB00819$drug$Sodium bicarbonate$DB01390$true$effect$drug$Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
DDI-DrugBank.d368.s14.p0$Acetazolamide$DB00819$drug$Cyclosporine$DB00091$true$mechanism$drug$Acetazolamide may elevate cyclosporine levels.
DDI-DrugBank.d368.s9.p0$Acetazolamide$DB00819$drug$Amphetamine$DB00182$true$mechanism$drug$Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
DDI-DrugBank.d371.s1.p0$Docetaxel$DB01248$drug$Cyclosporine$DB00091$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1.p1$Docetaxel$DB01248$drug$Terfenadine$DB00342$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1.p2$Docetaxel$DB01248$drug$Ketoconazole$DB01026$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1.p3$Docetaxel$DB01248$drug$Erythromycin$DB00199$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1.p4$Docetaxel$DB01248$drug$Troleandomycin$DB01361$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d372.s2.p1$Aminoglutethimide$DB00357$drug$Warfarin$DB00682$true$effect$drug$Aminoglutethimide diminishes the effect of coumarin and warfarin.
DDI-DrugBank.d373.s11.p5$Cimetidine$DB00501$drug$Nifedipine$DB01115$true$mechanism$drug$Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
DDI-DrugBank.d373.s14.p0$Nifedipine$DB01115$drug$Cimetidine$DB00501$true$advise$drug$If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
DDI-DrugBank.d373.s2.p14$Digoxin$DB00390$drug$Nifedipine$DB01115$true$advise$drug$Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s2.p9$Digoxin$DB00390$drug$Nifedipine$DB01115$true$int$drug$Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s3.p2$Digoxin$DB00390$drug$Digoxin$DB00390$true$mechanism$drug$Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
DDI-DrugBank.d373.s7.p2$Digoxin$DB00390$drug$Nifedipine$DB01115$true$advise$drug$Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s8.p3$Quinidine$DB00908$drug$Nifedipine$DB01115$true$mechanism$drug$Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
DDI-DrugBank.d374.s1.p0$Auranofin$DB00995$drug$Penicillamine$DB00859$true$advise$drug$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DDI-DrugBank.d382.s10.p0$Dexamethasone$DB01234$drug$Aprepitant$DB00673$true$advise$drug$The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s11.p0$Dexamethasone$DB01234$drug$Aprepitant$DB00673$true$mechanism$drug$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
DDI-DrugBank.d382.s13.p0$Aprepitant$DB00673$drug$Methylprednisolone$DB00959$true$mechanism$drug$Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
DDI-DrugBank.d382.s14.p1$Methylprednisolone$DB00959$drug$Aprepitant$DB00673$true$advise$drug$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s14.p4$Methylprednisolone$DB00959$drug$Aprepitant$DB00673$true$advise$drug$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s17.p0$Warfarin$DB00682$drug$Aprepitant$DB00673$true$advise$drug$In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
DDI-DrugBank.d382.s18.p9$Tolbutamide$DB01124$drug$Aprepitant$DB00673$true$mechanism$drug$Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
DDI-DrugBank.d382.s19.p7$Aprepitant$DB00673$drug$Ethinyl Estradiol$DB00977$true$mechanism$drug$Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
DDI-DrugBank.d382.s19.p8$Aprepitant$DB00673$drug$Norethindrone$DB00717$true$mechanism$drug$Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
DDI-DrugBank.d382.s22.p4$Aprepitant$DB00673$drug$Midazolam$DB00683$true$mechanism$drug$Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
DDI-DrugBank.d382.s23.p3$Midazolam$DB00683$drug$Aprepitant$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s23.p8$Alprazolam$DB00404$drug$Aprepitant$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s23.p9$Triazolam$DB00897$drug$Aprepitant$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s25.p0$Aprepitant$DB00673$drug$Midazolam$DB00683$true$mechanism$drug$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DDI-DrugBank.d382.s25.p1$Aprepitant$DB00673$drug$Midazolam$DB00683$true$mechanism$drug$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DDI-DrugBank.d382.s31.p0$Aprepitant$DB00673$drug$Ketoconazole$DB01026$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p1$Aprepitant$DB00673$drug$Itraconazole$DB01167$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p2$Aprepitant$DB00673$drug$Nefazodone$DB01149$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p3$Aprepitant$DB00673$drug$Troleandomycin$DB01361$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p4$Aprepitant$DB00673$drug$Clarithromycin$DB01211$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p5$Aprepitant$DB00673$drug$Ritonavir$DB00503$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p6$Aprepitant$DB00673$drug$Nelfinavir$DB00220$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s32.p0$Diltiazem$DB00343$drug$Aprepitant$DB00673$true$advise$drug$Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
DDI-DrugBank.d382.s34.p2$Aprepitant$DB00673$drug$Phenytoin$DB00252$true$mechanism$drug$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s34.p3$Aprepitant$DB00673$drug$Aprepitant$DB00673$true$mechanism$drug$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s36.p4$Aprepitant$DB00673$drug$Ketoconazole$DB01026$true$mechanism$drug$Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
DDI-DrugBank.d382.s4.p1$Aprepitant$DB00673$drug$Tolbutamide$DB01124$true$mechanism$drug$Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
DDI-DrugBank.d382.s41.p4$Aprepitant$DB00673$drug$Diltiazem$DB00343$true$mechanism$drug$Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
DDI-DrugBank.d382.s43.p4$Aprepitant$DB00673$drug$Paroxetine$DB00715$true$mechanism$drug$Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
DDI-DrugBank.d382.s5.p0$Aprepitant$DB00673$drug$Phenytoin$DB00252$true$mechanism$drug$Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
DDI-DrugBank.d382.s9.p11$Aprepitant$DB00673$drug$Dexamethasone$DB01234$true$mechanism$drug$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DDI-DrugBank.d382.s9.p18$Aprepitant$DB00673$drug$Dexamethasone$DB01234$true$mechanism$drug$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DDI-DrugBank.d384.s2.p11$Phenytoin$DB00252$drug$Calcitriol$DB00136$true$mechanism$drug$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d384.s2.p13$Phenobarbital$DB01174$drug$Calcitriol$DB00136$true$mechanism$drug$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d386.s23.p31$Desipramine$DB01151$drug$Chlordiazepoxide$DB00475$true$effect$drug$If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d386.s23.p32$Desipramine$DB01151$drug$Diazepam$DB00829$true$effect$drug$If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d387.s2.p0$Doxylamine$DB00366$drug$Epinephrine$DB00668$true$effect$drug$Doxylamine may enhance the effects of epinephrine.
DDI-DrugBank.d393.s2.p0$Theophylline$DB00277$drug$Cetirizine$DB00341$true$mechanism$drug$In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
DDI-DrugBank.d393.s5.p0$Cetirizine$DB00341$drug$Theophylline$DB00277$true$mechanism$drug$There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
DDI-DrugBank.d395.s0.p4$Bismuth Subsalicylate$DB01294$drug$Enoxacin$DB00467$true$mechanism$drug$Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
DDI-DrugBank.d395.s1.p0$Enoxacin$DB00467$drug$Bismuth Subsalicylate$DB01294$true$advise$drug$Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
DDI-DrugBank.d395.s17.p4$Aluminum hydroxide$DB06723$drug$Enoxacin$DB00467$true$mechanism$drug$Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
DDI-DrugBank.d395.s18.p0$Enoxacin$DB00467$drug$Ranitidine$DB00863$true$mechanism$drug$The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
DDI-DrugBank.d395.s21.p0$Enoxacin$DB00467$drug$Theophylline$DB00277$true$mechanism$drug$Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
DDI-DrugBank.d395.s22.p2$Theophylline$DB00277$drug$Enoxacin$DB00467$true$effect$drug$Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
DDI-DrugBank.d395.s25.p0$Warfarin$DB00682$drug$Enoxacin$DB00467$true$advise$drug$Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
DDI-DrugBank.d395.s3.p0$Enoxacin$DB00467$drug$Caffeine$DB00201$true$mechanism$drug$In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
DDI-DrugBank.d395.s4.p2$Caffeine$DB00201$drug$Enoxacin$DB00467$true$mechanism$drug$Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
DDI-DrugBank.d395.s5.p2$Caffeine$DB00201$drug$Enoxacin$DB00467$true$effect$drug$Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
DDI-DrugBank.d395.s7.p2$Enoxacin$DB00467$drug$Digoxin$DB00390$true$mechanism$drug$Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
DDI-DrugBank.d395.s8.p4$Enoxacin$DB00467$drug$Digoxin$DB00390$true$effect$drug$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
DDI-DrugBank.d397.s0.p0$Erythromycin$DB00199$drug$Theophylline$DB00277$true$effect$drug$Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
DDI-DrugBank.d397.s1.p5$Theophylline$DB00277$drug$Erythromycin$DB00199$true$advise$drug$In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
DDI-DrugBank.d397.s10.p1$Erythromycin$DB00199$drug$Terfenadine$DB00342$true$mechanism$drug$Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DDI-DrugBank.d397.s10.p2$Erythromycin$DB00199$drug$Astemizole$DB00637$true$mechanism$drug$Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DDI-DrugBank.d397.s12.p0$Terfenadine$DB00342$drug$Erythromycin$DB00199$true$effect$drug$In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
DDI-DrugBank.d397.s13.p0$Erythromycin$DB00199$drug$Cisapride$DB00604$true$effect$drug$There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DDI-DrugBank.d397.s13.p5$Cisapride$DB00604$drug$Erythromycin$DB00199$true$mechanism$drug$There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DDI-DrugBank.d397.s15.p0$Lovastatin$DB00227$drug$Erythromycin$DB00199$true$advise$drug$Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
DDI-DrugBank.d397.s2.p0$Erythromycin$DB00199$drug$Digoxin$DB00390$true$mechanism$drug$Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DDI-DrugBank.d397.s5.p0$Erythromycin$DB00199$drug$Ergotamine$DB00696$true$effect$drug$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d397.s5.p1$Erythromycin$DB00199$drug$Dihydroergotamine$DB00320$true$effect$drug$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d397.s6.p0$Erythromycin$DB00199$drug$Triazolam$DB00897$true$mechanism$drug$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s6.p1$Erythromycin$DB00199$drug$Midazolam$DB00683$true$mechanism$drug$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s8.p0$Erythromycin$DB00199$drug$Carbamazepine$DB00564$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p1$Erythromycin$DB00199$drug$Cyclosporine$DB00091$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p11$Erythromycin$DB00199$drug$Terfenadine$DB00342$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p12$Erythromycin$DB00199$drug$Astemizole$DB00637$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p2$Erythromycin$DB00199$drug$Tacrolimus$DB00864$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p3$Erythromycin$DB00199$drug$Hexobarbital$DB01355$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p4$Erythromycin$DB00199$drug$Phenytoin$DB00252$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p5$Erythromycin$DB00199$drug$Alfentanil$DB00802$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p6$Erythromycin$DB00199$drug$Cisapride$DB00604$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p7$Erythromycin$DB00199$drug$Disopyramide$DB00280$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p8$Erythromycin$DB00199$drug$Lovastatin$DB00227$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p9$Erythromycin$DB00199$drug$Bromocriptine$DB01200$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d399.s1.p0$Dapsone$DB00250$drug$Clofazimine$DB00845$true$advise$drug$If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
DDI-DrugBank.d4.s2.p0$Dyphylline$DB00651$drug$Probenecid$DB01032$true$mechanism$drug$Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
DDI-DrugBank.d40.s10.p1$Phenytoin$DB00252$drug$Amiodarone$DB01118$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p11$Phenytoin$DB00252$drug$Halothane$DB01159$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p12$Phenytoin$DB00252$drug$Isoniazid$DB00951$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p13$Phenytoin$DB00252$drug$Methylphenidate$DB00422$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p15$Phenytoin$DB00252$drug$Phenylbutazone$DB00812$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p19$Phenytoin$DB00252$drug$Tolbutamide$DB01124$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p2$Phenytoin$DB00252$drug$Chlordiazepoxide$DB00475$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p20$Phenytoin$DB00252$drug$Trazodone$DB00656$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p3$Phenytoin$DB00252$drug$Cimetidine$DB00501$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p4$Phenytoin$DB00252$drug$Diazepam$DB00829$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p6$Phenytoin$DB00252$drug$Disulfiram$DB00822$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p8$Phenytoin$DB00252$drug$Ethosuximide$DB00593$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p9$Phenytoin$DB00252$drug$Fluoxetine$DB00472$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s12.p0$Phenytoin$DB00252$drug$Carbamazepine$DB00564$true$mechanism$drug$- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s12.p2$Phenytoin$DB00252$drug$Reserpine$DB00206$true$mechanism$drug$- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s14.p0$Phenytoin$DB00252$drug$Phenobarbital$DB01174$true$mechanism$drug$- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
DDI-DrugBank.d40.s15.p0$Phenytoin$DB00252$drug$Phenobarbital$DB01174$true$effect$drug$Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s15.p1$Phenytoin$DB00252$drug$Valproic Acid$DB00313$true$effect$drug$Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s19.p10$Phenytoin$DB00252$drug$Theophylline$DB00277$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p3$Phenytoin$DB00252$drug$Digitoxin$DB01396$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p4$Phenytoin$DB00252$drug$Doxycycline$DB00254$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p6$Phenytoin$DB00252$drug$Furosemide$DB00695$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p9$Phenytoin$DB00252$drug$Quinidine$DB00908$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d41.s0.p8$Cholestyramine$DB01432$drug$Leflunomide$DB01097$true$mechanism$drug$Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
DDI-DrugBank.d410.s3.p14$Propranolol$DB00571$drug$Ergotamine$DB00696$true$effect$drug$Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
DDI-DrugBank.d413.s16.p8$Ampicillin$DB00415$drug$Allopurinol$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DDI-DrugBank.d413.s16.p9$Amoxicillin$DB01060$drug$Allopurinol$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DDI-DrugBank.d413.s18.p4$Cyclophosphamide$DB00531$drug$Allopurinol$DB00437$true$effect$drug$Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
DDI-DrugBank.d413.s2.p10$Allopurinol$DB00437$drug$Azathioprine$DB00993$true$mechanism$drug$Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DDI-DrugBank.d413.s2.p9$Allopurinol$DB00437$drug$Mercaptopurine$DB01033$true$mechanism$drug$Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DDI-DrugBank.d413.s20.p4$Chlorpropamide$DB00672$drug$Allopurinol$DB00437$true$mechanism$drug$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DDI-DrugBank.d413.s20.p9$Allopurinol$DB00437$drug$Chlorpropamide$DB00672$true$mechanism$drug$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DDI-DrugBank.d413.s21.p0$Allopurinol$DB00437$drug$Chlorpropamide$DB00672$true$effect$drug$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
DDI-DrugBank.d413.s4.p18$Allopurinol$DB00437$drug$Mercaptopurine$DB01033$true$advise$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DDI-DrugBank.d413.s4.p19$Allopurinol$DB00437$drug$Azathioprine$DB00993$true$advise$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DDI-DrugBank.d414.s4.p0$Ethacrynic acid$DB00903$drug$Warfarin$DB00682$true$mechanism$drug$A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
DDI-DrugBank.d415.s12.p3$Ibuprofen$DB01050$drug$Lithium$DB01356$true$mechanism$drug$Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
DDI-DrugBank.d415.s15.p0$Ibuprofen$DB01050$drug$Lithium$DB01356$true$advise$drug$Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d415.s5.p4$Ibuprofen$DB01050$drug$Methotrexate$DB00563$true$mechanism$drug$Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
DDI-DrugBank.d415.s6.p0$Ibuprofen$DB01050$drug$Methotrexate$DB00563$true$effect$drug$This may indicate that ibuprofen could enhance the toxicity of methotrexate.
DDI-DrugBank.d415.s7.p0$Ibuprofen$DB01050$drug$Methotrexate$DB00563$true$advise$drug$Caution should be used if ibuprofen is administered concomitantly with methotrexate.
DDI-DrugBank.d415.s9.p3$Ibuprofen$DB01050$drug$Furosemide$DB00695$true$effect$drug$Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d417.s0.p1$Netilmicin$DB00955$drug$Furosemide$DB00695$true$advise$drug$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d417.s0.p2$Netilmicin$DB00955$drug$Ethacrynic acid$DB00903$true$advise$drug$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d419.s0.p0$Allopurinol$DB00437$drug$Ampicillin$DB00415$true$effect$drug$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
DDI-DrugBank.d419.s1.p0$Ampicillin$DB00415$drug$Allopurinol$DB00437$true$effect$drug$It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
DDI-DrugBank.d42.s1.p3$Dolasetron$DB00757$drug$Cimetidine$DB00501$true$mechanism$drug$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DDI-DrugBank.d420.s11.p0$Cefdinir$DB00535$drug$Iron$DB01592$true$mechanism$drug$The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
DDI-DrugBank.d420.s4.p7$Probenecid$DB01032$drug$Cefdinir$DB00535$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
DDI-DrugBank.d420.s5.p12$Cefdinir$DB00535$drug$Iron$DB01592$true$mechanism$drug$Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
DDI-DrugBank.d420.s5.p14$Cefdinir$DB00535$drug$Iron$DB01592$true$mechanism$drug$Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
DDI-DrugBank.d427.s5.p4$Nalidixic Acid$DB00779$drug$Warfarin$DB00682$true$effect$drug$Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d427.s7.p0$Nitrofurantoin$DB00698$drug$Nalidixic Acid$DB00779$true$effect$drug$Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
DDI-DrugBank.d428.s10.p0$Cimetidine$DB00501$drug$Epirubicin$DB00445$true$mechanism$drug$Cimetidine increased the AUC of epirubicin by 50%.
DDI-DrugBank.d429.s0.p9$Kaolin$DB01575$drug$Chloroquine$DB00608$true$mechanism$drug$Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
DDI-DrugBank.d429.s2.p2$Cimetidine$DB00501$drug$Chloroquine$DB00608$true$mechanism$drug$Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
DDI-DrugBank.d429.s4.p2$Chloroquine$DB00608$drug$Ampicillin$DB00415$true$mechanism$drug$Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
DDI-DrugBank.d43.s10.p2$Ciprofloxacin$DB00537$drug$Didanosine$DB00900$true$mechanism$drug$The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
DDI-DrugBank.d43.s11.p0$Ciprofloxacin$DB00537$drug$Didanosine$DB00900$true$mechanism$drug$In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
DDI-DrugBank.d43.s8.p19$Ciprofloxacin$DB00537$drug$Magnesium$DB01378$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s8.p20$Ciprofloxacin$DB00537$drug$Calcium$DB01373$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d430.s0.p0$Ranitidine$DB00863$drug$Alendronate$DB00630$true$mechanism$drug$Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
DDI-DrugBank.d430.s3.p1$Calcium$DB01373$drug$Alendronate$DB00630$true$mechanism$drug$Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
DDI-DrugBank.d431.s12.p0$Lansoprazole$DB00448$drug$Ketoconazole$DB01026$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s12.p1$Lansoprazole$DB00448$drug$Ampicillin$DB00415$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s12.p2$Lansoprazole$DB00448$drug$Iron$DB01592$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s12.p3$Lansoprazole$DB00448$drug$Digoxin$DB00390$true$mechanism$drug$therefore, i